<DOC>
	<DOCNO>NCT01833533</DOCNO>
	<brief_summary>The purpose study evaluate safety antiviral activity ABT-450/ritonavir/ABT- 267 ( ABT-450/r/ABT-267 ; ABT-450 also know paritaprevir ; ABT-267 also know ombitasvir ) ABT-333 ( also know dasabuvir ) without ribavirin ( RBV ) patient chronic hepatitis C virus genotype 1a ( HCV GT1a ) infection without cirrhosis .</brief_summary>
	<brief_title>A Study Evaluate Chronic Hepatitis C Infection Adults With Genotype 1a Infection</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled , multicenter study evaluate safety antiviral activity combination ABT-450/ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) ABT-333 without ribavirin ( RBV ) treatment-naive , noncirrhotic participant chronic hepatitis C virus genotype 1a ( HCV GT1a ) infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Females must practice specific form birth control study treatment , postmenopausal 2 year surgically sterile Chronic hepatitis C , genotype 1ainfection ( HCV RNA level great equal 10,000 IU/mL screen ) Subject never receive antiviral treatment hepatitis C infection No evidence liver cirrhosis Significant liver disease cause HCV primary cause Positive hepatitis B surface antigen antihuman immunodeficiency virus antibody Positive screen drug alcohol Significant sensitivity drug Use contraindicate medication within 2 week dose Abnormal laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 1a</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment-Na√Øve</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Viekira PAK</keyword>
</DOC>